Azitra, Inc. (AZTR) - Q2 2024 10-Q Summary
Business Context and Reporting Period
Azitra, Inc. is an early-stage clinical biopharmaceutical company focused on developing genetically engineered microbes and proteins for precision dermatology. The company is in the pre-commercialization phase with no product revenue. This report covers the quarterly period ended June 30, 2024. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|
| Total Revenue | $7,500 | $7,500 | $285,300 |
| Net Loss | $(2,631,993) | $(5,564,868) | $(6,886,707) |
| Operating Expenses | $2,667,780 | $5,629,277 | $3,271,636 |
| Cash and Equivalents (End of Period) | $803,082 | $803,082 | $6,290,355 |
| Working Capital | $(403,341) | $(403,341) | N/A |
| Accumulated Deficit | $(54,163,201) | $(54,163,201) | $(48,597,163) |
Note: Revenue consists entirely of service revenue from a related party (Bayer) under a Joint Development Agreement.
Material Changes vs. Prior Period
- Revenue Decline: Revenue dropped 96% in Q2 2024 compared to Q2 2023 ($7,500 vs. $172,000) due to a decrease in reimbursable development costs under the Bayer agreement.
- Expense Increase: Operating expenses increased 67% in Q2 2024 ($2.67M vs. $1.60M). General and Administrative (G&A) costs rose 83% primarily due to public company costs (NYSE listing, D&O insurance, legal, and executive hiring). R&D costs rose 48% driven by clinical trial preparations for ATR-12 and ATR-04.
- Net Loss Improvement: Despite higher operating expenses, the net loss decreased 41% in Q2 2024 compared to the prior year. This was largely due to the absence of a $2.83M non-cash loss on the change in fair value of convertible notes recorded in Q2 2023.
- Cash Burn: Net cash used in operating activities for the six months ended June 30, 2024, was $5.12 million, compared to $3.03 million in the prior year period.
Outlook, Risks, and Subsequent Events
- Going Concern: Management has identified substantial doubt about the company's ability to continue as a going concern for twelve months from the report date due to an accumulated deficit of $54.2 million, negative working capital, and the need for significant additional funding.
- Subsequent Financing: On July 25, 2024, the company completed a follow-on offering of 6,665,000 shares and warrants, raising approximately $10.0 million in gross proceeds (net proceeds estimated at $8.95 million). Management believes this, combined with cash on hand, may still not be sufficient to cover operations for the next twelve months.
- Stock Split: A 30-for-1 reverse stock split was effected on July 1, 2024. All share and per-share data in this filing have been retroactively adjusted.
- Internal Controls: The company identified a material weakness in internal controls related to a lack of adequate segregation of accounting functions.
- Product Pipeline: The company expects to report initial safety results for ATR-12 (Netherton syndrome) by year-end 2024 and plans to commence a Phase 1b trial for ATR-04 (EGFRi rash) in Q4 2024.
Investor Verification Checklist
- Liquidity Runway: Verify if the $8.95 million net proceeds from the July 2024 offering are sufficient to fund operations through the next 12 months, given management's expressed doubt.
- Revenue Concentration: Confirm the status of the Joint Development Agreement with Bayer, as 100% of revenue is derived from this single related party.
- Capital Structure: Review the impact of the July 2024 offering and the 30-for-1 reverse stock split on share count and potential dilution.
- Internal Controls: Monitor remediation efforts regarding the material weakness in segregation of accounting duties.
- Clinical Milestones: Track the timeline for the ATR-12 safety results (expected year-end 2024) and the ATR-04 IND filing (expected Q3 2024).